Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02743741
• Other study ID #: OZM-067
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 15, 2016
• Est. completion date: June 2026

Study information

• Verified date: July 2023
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 195
• Est. completion date: June 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Please note that only Ontario residents will be eligible for participation in this trial.

Inclusion Criteria:

1. Biopsy-proven neuroendocrine tumor

2. ECOG performance status = 2

3. Ki-67 index = 30%

4. Evidence of progressive disease demonstrated by imaging within six months prior to study enrollment as defined by RECIST v1.1.

• Tumor board discussion of cases to confirm suitability for participation in the clinical trial is required. Review should include but not limited to imaging review, pathology (including Ki 67) and treatment options.

• Patients with objective evidence (imaging, or biochemical) that is insufficient to be classified by RECIST 1.1 criteria can be eligible if after provincial multidisciplinary tumor board discussion a consensus for progression eligibility is reached.

• The tumor board would consider exemptions if the magnitude of change is adequate by other definitions (e.g. using structural and contrast patterns and biochemical changes).

• Where clinically indicated, formal consultation on pathology, diagnostic imaging to facilitate criteria assessment (including 68Ga PET performed as part of the diagnostic procedure) is strongly recommended.

5. Adequate lab parameters within 2 weeks prior to enrollment:

• Serum creatinine = 150 µmol/L

• Calculated CrCl or measured GFR = 30 mL/min (measured GFR may be done within 4 weeks prior to enrollment)

• Haemoglobin = 90 g/L

• WBC = 2 x 109/L

• Platelets = 100 x 109/L

6. Adequate liver function tests within 2 weeks prior to enrollment:

• total bilirubin = 5 x ULN

• ALT = 5 x ULN

• AST = 5 x ULN

• alkaline phosphatase = 5 x ULN

7. Signed informed consent

8. Patients with extensive bone metastases (e.g. >25% of bone marrow involvement are eligible but requires careful monitoring of hematological reserve

9. Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

10. Age = 18 years.

Exclusion Criteria:

1. Life expectancy <12 weeks

2. An option for curative surgical or medical therapy or local liver embolization is feasible

3. Candidate for curative and/or debulking surgical resections

4. Systemic, biologic, other radioisotope, embolization therapies within =4 weeks prior to the first dose of 177Lu.

5. Prior radiotherapy to target lesion(s) within =12 weeks prior to study enrollment [radiotherapy to non-target lesions permitted].

6. Prior therapy with any systemic radionuclide therapy.

7. Radiotherapy to more than 25% of the bone marrow.

8. Known brain metastases (unless metastases have been treated and are stable for = 6 months).

9. Uncontrolled diabetes mellitus

10. Co-morbidities that may interfere with delivery of 177Lu (e.g. urinary incontinence).

11. Second cancer(s) with clinical or biochemical progression within the last 3 years.

12. Pregnancy or breast feeding. Female subjects must be surgically sterile or postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrolment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate

13. Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation, 68Ga or 177Lu administration, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Drug:
• Lutetium-177 Octreotate
Radiopharmaceutical

Locations

Country	Name	City	State
Canada	Juravinski Cancer Centre	Hamilton	Ontario
Canada	London Health Sciences Centre	London	Ontario
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Canada	Sunnybrook Odette Cancer Center	Toronto	Ontario

Sponsors (4)

Lead Sponsor	Collaborator
University Health Network, Toronto	Canadian Molecular Imaging Probe Consortium, Cancer Care Ontario, Ozmosis Research Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients progression-free using RECIST 1.1 criteria		Up to 12 months
Secondary	The overall response rate as determined by structural imaging using RECIST criteria.		Up to 5 years
Secondary	The biochemical response rate (as defined by biochemical responses: serum chromogranin A and 24 hr urinary 5HIAA).		Up to 5 years
Secondary	The acute and late adverse effects of Lu-DOTATATE (177Lu) using CTCAE Version 4.03		Up to 5 years
Secondary	Overall survival		Up to 5 years
Secondary	The Quality of Life (QoL) in patients treated with Lu-DOTATATE (177Lu)		Up to 5 years